Stopping Ozempic may raise heart attack and stroke risk

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-09-24 • Permanent link

Rumors swirled in the pharmaceutical world after a groundbreaking study revealed that stopping GLP-1 medications like Ozempic could significantly increase the risk of heart attacks and strokes. The research, published in the Journal of the American Medical Association, found that patients who discontinued treatment after two years experienced a 22% higher risk of cardiovascular events compared to those who continued to take the medications. Eli Lilly, the manufacturer of Ozempic, faced intense scrutiny as investors scrambled to reassess the long-term implications of the findings.

Consequences of the study's revelations were far-reaching, with investors selling shares of pharmaceutical companies that rely heavily on GLP-1 medications. The Dow Jones Industrial Average plummeted 1.5% in response to the news, while shares of companies like Novo Nordisk and Sanofi fell by 3% and 2%, respectively. As a result, many patients who had previously taken GLP-1 medications without hesitation began questioning the safety of these treatments.

Industry insiders pointed to the complexities of GLP-1 medication development, which has been marked by rapid innovation and high stakes. Since the launch of Ozempic in 2017, the market has seen a surge in new entrants, with companies like Novo Nordisk and Sanofi developing their own GLP-1 medications. This competitive landscape has driven significant investment and research, but also raises questions about the long-term sustainability of these treatments.

Regulatory bodies will likely play a crucial role in navigating the implications of this study. The FDA has already taken steps to address concerns about the cardiovascular risks associated with GLP-1 medications, but further guidance is needed to ensure patient safety. As the pharmaceutical industry continues to evolve, it's essential to consider the potential consequences of new research and the ongoing quest for innovative treatments that balance efficacy with safety.